Financhill
Sell
39

MEDP Quote, Financials, Valuation and Earnings

Last price:
$347.48
Seasonality move :
-0.24%
Day range:
$335.46 - $343.85
52-week range:
$286.76 - $459.77
Dividend yield:
0%
P/E ratio:
29.54x
P/S ratio:
5.21x
P/B ratio:
11.90x
Volume:
198.1K
Avg. volume:
241.3K
1-year change:
18.42%
Market cap:
$10.5B
Revenue:
$1.9B
EPS (TTM):
$11.42

Analysts' Opinion

  • Consensus Rating
    Medpace Holdings has received a consensus rating of Hold. The company's average rating is a Hold based on 4 Buy ratings, 6 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $347.92, Medpace Holdings has an estimated upside of 3.13% from its current price of $337.35.
  • Price Target Downside
    According to analysts, the lowest downside price target is $296.00 representing -- downside risk from its current price of $337.35.

Fair Value

  • According to the consensus of 10 analysts, Medpace Holdings has 3.13% upside to fair value with a price target of $347.92 per share.

MEDP vs. S&P 500

  • Over the past 5 trading days, Medpace Holdings has underperformed the S&P 500 by -2.83% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Medpace Holdings does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Medpace Holdings has grown year-over-year revenues for 17 quarters straight. In the most recent quarter Medpace Holdings reported revenues of $533.3M.

Earnings Growth

  • Medpace Holdings has grown year-over-year earnings for 11 quarters straight. In the most recent quarter Medpace Holdings reported earnings per share of $3.01.
Enterprise value:
9.8B
EV / Invested capital:
--
Price / LTM sales:
5.21x
EV / EBIT:
24.04x
EV / Revenue:
4.75x
PEG ratio (5yr expected):
0.88x
EV / Free cash flow:
18.35x
Price / Operating cash flow:
20.16x
Enterprise value / EBITDA:
22.46x
Gross Profit (TTM):
$614.8M
Return On Assets:
20.44%
Net Income Margin (TTM):
17.66%
Return On Equity:
54.64%
Return On Invested Capital:
54.64%
Operating Margin:
21.05%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue $1.4B $1.8B $2.1B $492.5M $533.3M
Gross Profit $404.7M $503.4M $614.8M $133.2M $169M
Operating Income $257.1M $325.9M $408.8M $84.9M $112.3M
EBITDA $284.7M $342.2M $437.5M $91.8M $119.8M
Diluted EPS $6.52 $8.54 $11.42 $2.22 $3.01
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets $395M $641.2M $337.7M $448.9M $1B
Total Assets $1.3B $1.6B $1.3B $1.5B $2.1B
Current Liabilities $358.4M $517.2M $820.9M $848.5M $1B
Total Liabilities $504.5M $679.1M $978.5M $1B $1.2B
Total Equity $791.6M $898.1M $349.9M $470.9M $881.4M
Total Debt -- -- $139.7M -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations $322.3M $413.7M $574.5M $114.4M $149.1M
Cash From Investing -$38.6M -$35.9M -$28.7M -$8.7M -$10.5M
Cash From Financing -$642.2M -$315.3M $16.1M -$49.3M $6.3M
Free Cash Flow $285.5M $377.8M $535.7M $105.7M $138.5M
MEDP
Sector
Market Cap
$10.5B
$44.7M
Price % of 52-Week High
--
51.72%
Dividend Yield
0%
0%
Shareholder Yield
0.11%
-0.75%
1-Year Price Total Return
18.42%
-33.41%
Beta (5-Year)
1.363
0.746
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Sell
Level $343.07
200-day SMA
Sell
Level $369.95
Bollinger Bands (100)
Sell
Level 327.73 - 358.29
Chaikin Money Flow
Buy
Level 26.4M
20-day SMA
Sell
Level $339.82
Relative Strength Index (RSI14)
Sell
Level 47.29
ADX Line
Sell
Level 20.06
Williams %R
Neutral
Level -68.2703
50-day SMA
Sell
Level $341.25
MACD (12, 26)
Sell
Level -0.40
25-day Aroon Oscillator
Buy
Level 52
On Balance Volume
Neutral
Level 39.6M

Financial Scores

Buy
Altman Z-Score (Annual)
Level (6.5335)
Buy
CA Score (Annual)
Level (0.1831)
--
Beneish M-Score (Annual)
Level (--)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (0.7343)
Buy
Piotroski F Score (Annual)
Level (7)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (6)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the us, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.

Stock Forecast FAQ

In the current month, MEDP has received 4 Buy ratings 6 Hold ratings, and 0 Sell ratings. The MEDP average analyst price target in the past 3 months is $347.92.

  • Where Will Medpace Holdings Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Medpace Holdings share price will rise to $347.92 per share over the next 12 months.

  • What Do Analysts Say About Medpace Holdings?

    Analysts are divided on their view about Medpace Holdings share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Medpace Holdings is a Sell and believe this share price will drop from its current level to $296.00.

  • What Is Medpace Holdings's Price Target?

    The price target for Medpace Holdings over the next 1-year time period is forecast to be $347.92 according to 10 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 6 analysts rate the stock a Hold.

  • Is MEDP A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Medpace Holdings is a Hold. 6 of 10 analysts rate the stock a Hold at this time.

  • How Can I Buy Shares Of MEDP?

    You can purchase shares of Medpace Holdings via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Medpace Holdings shares.

  • What Is The Medpace Holdings Share Price Today?

    Medpace Holdings was last trading at $347.48 per share. This represents the most recent stock quote for Medpace Holdings. Yesterday, Medpace Holdings closed at $337.35 per share.

  • How To Buy Medpace Holdings Stock Online?

    In order to purchase Medpace Holdings stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Sirius XM Be a 10-Bagger Stock?
Will Sirius XM Be a 10-Bagger Stock?

Last year, Warren Buffett surprised practically everyone when he acquired…

Will Quantum Computing Disrupt NVIDIA?
Will Quantum Computing Disrupt NVIDIA?

Earlier this month, NVIDIA CEO Jensen Huang seemingly dashed the…

What Trump Presidency Means For Stock Market
What Trump Presidency Means For Stock Market

Donald Trump was the first president in modern U.S. history…

Stock Ideas

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 38x

Buy
51
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 115x

Buy
53
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 36x

Alerts

Buy
59
NUKK alert for Jan 21

Nukkleus [NUKK] is up 7.25% over the past day.

Sell
45
QMCO alert for Jan 21

Quantum [QMCO] is up 14.36% over the past day.

Buy
51
QRVO alert for Jan 21

Qorvo [QRVO] is up 3.99% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock